Iovance Biotherapeutics (IOVA) Misses Q2 EPS by 3c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.34), $0.03 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• JPMorgan Upgrades Primoris Services Corporation (PRIM) to Overweight
• Pattern Group Inc (PTRN) PT Raised to $27 at Goldman Sachs